Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹934 Cr revenue.
COGS 28.1%, employees 15.2%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 43.7%▲ | 10.5% |
| ROCE | 53.9%▲ | 13.8% |
| Net Margin | 24.8%▲ | 8.7% |
| EBITDA Margin | 34.8%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹934 Cr -18.9% | ₹1,151 Cr -6.4% | ₹1,230 Cr +10.3% | ₹1,114 Cr +10.5% | ₹1,009 Cr 0.0% | ₹1,009 Cr +8.9% | ₹927 Cr |
| Other Income | ₹10 Cr -33.8% | ₹16 Cr -15.0% | ₹18 Cr +39.4% | ₹13 Cr -27.1% | ₹18 Cr 0.0% | ₹18 Cr -62.2% | ₹48 Cr |
| Total Income | ₹945 Cr -19.1% | ₹1,167 Cr -6.5% | ₹1,248 Cr +10.7% | ₹1,128 Cr +9.8% | ₹1,027 Cr 0.0% | ₹1,027 Cr +5.4% | ₹975 Cr |
| COGS | ₹263 Cr -20.6% | ₹331 Cr -8.6% | ₹362 Cr +6.5% | ₹340 Cr +7.9% | ₹315 Cr 0.0% | ₹315 Cr +5.0% | ₹300 Cr |
| ₹633 Cr -27.5% | ₹873 Cr -6.5% | ₹934 Cr +6.8% | ₹874 Cr +10.2% | ₹794 Cr 0.0% | ₹794 Cr +7.2% | ₹740 Cr | |
| Profit Before Tax | ₹312 Cr +14.0% | ₹273 Cr -13.0% | ₹314 Cr +24.0% | ₹253 Cr +8.6% | ₹233 Cr 0.0% | ₹233 Cr -0.5% | ₹234 Cr |
| Exceptional Items | ₹0.00 Cr +100.0% | (₹20 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹77 Cr +6.7% | ₹72 Cr -14.6% | ₹85 Cr +39.2% | ₹61 Cr +7.7% | ₹56 Cr 0.0% | ₹56 Cr -25.3% | ₹76 Cr | |
| Net Profit | ₹234 Cr +16.6% | ₹201 Cr -12.4% | ₹229 Cr +19.2% | ₹193 Cr +8.9% | ₹177 Cr 0.0% | ₹177 Cr +11.4% | ₹159 Cr |
| Other Comprehensive Income | (₹3 Cr) ↓ Decline | ₹0.67 Cr ↑ Recovery | (₹2 Cr) ↓ Decline | ₹0.70 Cr +66.7% | ₹0.42 Cr 0.0% | ₹0.42 Cr ↑ Recovery | (₹1 Cr) |
| EPS | ₹141.22 | ₹121.08 | ₹138.24 | ₹115.98 | ₹106.51 | ₹106.51 | ₹95.64 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Procter & Gamble Health Limited has informed the Exchange about Schedule of meet
Procter & Gamble Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Procter & Gamble Health Limited has informed the Exchange about General Updates
Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Procter & Gamble Health Limited has informed the Exchange regarding a Press release on unaudited Financial Results for the quarter ended December 31, 2025.
Procter & Gamble Health Limited has informed the Exchange that Record date for the purpose of Dividend is 12-Feb-2026.
Procter & Gamble Health Limited has informed the Exchange that Board of Directors at its meeting held on February 06, 2026, declared Interim Dividend of 160 per equity share (including a one-time spec...
Procter & Gamble Health Limited has informed the Exchange that Board of Directors at its meeting held on February 06, 2026, declared Interim Dividend of Rs. 160 per equity share (including a one-time ...
Procter & Gamble Health Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Procter & Gamble Health Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Procter & Gamble Health Limited has informed the Exchange about Appointment of Mr. Shashank Srowthy (11317956) as an Executive Director of the Company- via postal ballot
Procter & Gamble Health Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report.
Procter & Gamble Health Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Press release for the quarter ended September 30, 2025".
Procter & Gamble Health Limited has informed the Exchange regarding Board meeting held on November 05, 2025.
Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.